These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31981585)

  • 1. The exchangeable apolipoproteins in lipid metabolism and obesity.
    Su X; Peng D
    Clin Chim Acta; 2020 Apr; 503():128-135. PubMed ID: 31981585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular role of exchangeable apolipoproteins in energy homeostasis, obesity and non-alcoholic fatty liver disease.
    Wu CL; Zhao SP; Yu BL
    Biol Rev Camb Philos Soc; 2015 May; 90(2):367-76. PubMed ID: 24834836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients.
    Su X; Kong Y; Peng DQ
    Lipids Health Dis; 2018 Jul; 17(1):174. PubMed ID: 30053818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease.
    Dai W; Zhang Z; Yao C; Zhao S
    Lipids Health Dis; 2019 Dec; 18(1):220. PubMed ID: 31836003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.
    Arnedo M; Taffé P; Sahli R; Furrer H; Hirschel B; Elzi L; Weber R; Vernazza P; Bernasconi E; Darioli R; Bergmann S; Beckmann JS; Telenti A; Tarr PE;
    Pharmacogenet Genomics; 2007 Sep; 17(9):755-64. PubMed ID: 17700364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum apolipoprotein C3 levels are negatively associated with hepatitis B virus DNA in HBeAg-negative chronic hepatitis B patients.
    Cui Y; Cui XD; Xu M; Fang M; Cai MJ
    Lipids Health Dis; 2019 Jun; 18(1):138. PubMed ID: 31186008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-α mediated apolipoprotein A-I, A-II and C-III.
    Liu C; Guo Q; Lu M; Li Y
    Eur J Pharmacol; 2015 Aug; 761():362-74. PubMed ID: 25979856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes.
    Qi L; Liu S; Rifai N; Hunter D; Hu FB
    Atherosclerosis; 2007 May; 192(1):204-10. PubMed ID: 16781717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk.
    Lai CQ; Parnell LD; Ordovas JM
    Curr Opin Lipidol; 2005 Apr; 16(2):153-66. PubMed ID: 15767855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic basis of dyslipidemia in disease precipitation of coronary artery disease (CAD) associated type 2 diabetes mellitus (T2DM).
    Raj R; Bhatti JS; Badada SK; Ramteke PW
    Diabetes Metab Res Rev; 2015 Oct; 31(7):663-71. PubMed ID: 25470794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of apolipoprotein E polymorphism with plasma lipid disorders, independent of obesity-related traits in Vietnamese children.
    Hanh NT; Nhung BT; Dao DT; Tuyet LT; Hop LT; Binh TQ; Thuc VT
    Lipids Health Dis; 2016 Oct; 15(1):176. PubMed ID: 27724906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into the mechanism of low high-density lipoprotein cholesterol in obesity.
    Wang H; Peng DQ
    Lipids Health Dis; 2011 Oct; 10():176. PubMed ID: 21988829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia.
    Mar R; Pajukanta P; Allayee H; Groenendijk M; Dallinga-Thie G; Krauss RM; Sinsheimer JS; Cantor RM; de Bruin TW; Lusis AJ
    Circ Res; 2004 Apr; 94(7):993-9. PubMed ID: 15001527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?
    Jakel H; Nowak M; Helleboid-Chapman A; Fruchart-Najib J; Fruchart JC
    Ann Med; 2006; 38(1):2-10. PubMed ID: 16448983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
    Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
    Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.